Shogo Kawaguchi

Shogo Kawaguchi

Auto-generated profile, based on publicly available information

Shogo Kawaguchi

Department of Vascular and Inflammatory Medicine, Biomedical Research Center, Hirosaki University Graduate School of Medicine, Hirosaki, Japan

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2019 in Modern Rheumatology
Verified
Journal Article
Closed access
KHKoji Hirono
Koji Hirono
TITadaatsu Imaizumi
Tadaatsu Imaizumi
TATomomi Aizawa
Tomomi Aizawa
SWShojiro Watanabe
Shojiro Watanabe
KTKOJI TSUGAWA
KOJI TSUGAWA
Hiroshi TanakaHiroshi Tanaka
Hiroshi Tanaka
Background: Endothelial expression of membrane-bound fractalkine/CX3CL1 (Fkn) reportedly acts as a strong mediator of inflammation. Toll-like receptor 3 (TLR3) axes are thought to play some roles in the development of chronic glomerulonephritis (CGN) including lupus nephritis (LN). However, detailed mechanism of TLR3-mediated Fkn expression in glomerular endothelial cells (GECs) remains to be elucidated. Methods: We examined the effect of polyinosinic-polycytidylic acid (poly IC) on Fkn expression in cultured human GECs. Fkn mRNA and protein levels were quantified by real-time PCR and enzyme-linked immunosorbent assay, respectively. To further elucidate the effects of poly IC on this signaling pathway, we used small interfering RNA (siRNA) to knockdown expression of TLR3, nuclear factor (NF)-κB p65, interferon (IFN)-β, and IFN regulatory factor 3 (IRF3). We then analyzed whether pretreatment of chloroquine or dexamethasone inhibits poly IC-induced Fkn expression. Results: We found that poly IC-induced Fkn expression in GECs, and that this involved NF-κB, IFN-β, and IRF3. Pretreating cells with chloroquine, but not dexamethasone attenuated poly IC-induced Fkn expression in GECs. Conclusion: Since the activation of TLR3/NF-κB/IFN-β/Fkn and TLR3/IRF3/Fkn axes is involved in inflammatory reactions in GECs, intervention of glomerular TLR3 signaling may be a suitable therapeutic strategy for treating CGN especially LN.

16 December 2020 in Kidney and Blood Pressure Research
Verified
Journal Article
Open access
PDF file
TITadaatsu Imaizumi
Tadaatsu Imaizumi
SHShun Hashimoto
Shun Hashimoto
RSRiko Sato
Riko Sato
HUHidenori Umetsu
Hidenori Umetsu
TATomomi Aizawa
Tomomi Aizawa
HTHiroshi Tanaka
Hiroshi Tanaka
Introduction: Various viruses including a novel coronavirus (SARS-CoV-2) can infect the kidney. When viruses invade the glomeruli from the bloodstream, glomerular endothelial cells (GECs) initiate the innate immune reactions. We investigated the expression of interferon (IFN)-induced protein with tetratricopeptide repeats (IFIT) 1/2/3, antiviral molecules, in human GECs treated with a toll-like receptor (TLR) 3 agonist. Role of IFIT1/2/3 in the expression of C-X-C motif chemokine ligand 10 (CXCL10) was also examined. Methods: Human GECs were cultured and stimulated with polyinosinic-polycytidylic acid (poly IC), a synthetic TLR3 agonist. Real-time qPCR, Western blotting, and ELISA were used to examine the expression of IFIT1/2/3, IFN-β, and CXCL10. RNA interference against IFN-β or IFIT1/2/3 was also performed. Results: Expression of IFIT1/2/3 and CXCL10 was induced by poly IC in GECs. The inductions were inhibited by RNA interfering of IFN-β. Knockdown of IFIT1/2/3 decreased the CXCL10 expression. Knockdown of IFIT3 decreased the expression of IFIT1 and IFIT2 proteins. Conclusion: IFIT1/2/3 and CXCL10 were induced by poly IC via IFN-β in GECs. IFIT1/2/3 may increase the expression of CXCL10 which induces lymphocyte chemotaxis and may inhibit the replication of infected viruses. These molecules may play a role in GEC innate immune reactions in response to viruses.

1 January 2021 in Molecular Immunology
Verified
Journal Article
Closed access
SKShogo Kawaguchi
Shogo Kawaguchi
HSHirotake Sakuraba
Hirotake Sakuraba
HKHidezumi Kikuchi
Hidezumi Kikuchi
NNNoriyuki Numao
Noriyuki Numao
TATaka Asari
Taka Asari
TITadaatsu Imaizumi
Tadaatsu Imaizumi

30 January 2022 in Intestinal Research
Verified
Journal Article
Open access
PDF file
TMTakato Maeda
Takato Maeda
HSHirotake Sakuraba
Hirotake Sakuraba
HHHiroto Hiraga
Hiroto Hiraga
SYShukuko Yoshida
Shukuko Yoshida
YKYoichi Kakuta
Yoichi Kakuta
SFShinsaku Fukuda
Shinsaku Fukuda
Background/Aims: Thiopurines are key drugs for inflammatory bowel disease (IBD), including ulcerative colitis (UC) and Crohn’s disease (CD). Recently, NUDT15 polymorphism (R139C, c.415C > T) has been shown to be associated with thiopurineinduced adverse events in Asian populations. In patients with the C/T genotype, low-dose thiopurine treatment is recommended, but its long-term efficacy and tolerability remain unclear. This study aimed to uncover the long-term efficacy and appropriate dosage of thiopurine for IBD patients with the C/T genotype.Methods: A total of 210 patients with IBD (103 UC and 107 CD) determined to have NUDT15 R139C variants were enrolled. Clinical data were retrospectively reviewed from medical records.Results: Of 46 patients (21.9%) with the C/T genotype, 30 patients (65.2%) were treated with thiopurines. Three of whom (10.0%) discontinued thiopurine treatment due to adverse events and 27 of whom continued. The median maintenance dosage of 6-mercaptopurine was 0.25 mg/kg/day (range, 0.19–0.36 mg/kg/day), and 6-thioguanine nucleotides level was 230 (104–298) pmol/8 × 108 red blood cells. Cumulative thiopurine continuation rates for 120 months for patients with the C/C and C/T genotypes were not significantly different (P= 0.895). Cumulative non-relapse rates in the patients with UC treated with thiopurine monotherapy and surgery-free rates in CD patients treated with combination therapy (thiopurines and anti-tumor necrosis factor-α agents) for maintenance remission were not significantly different at 60 months (C/C vs. C/T, P= 0.339 and P= 0.422, respectively).Conclusions: Low-dose thiopurine treatment is an effective and acceptable treatment for patients with C/T genotype.

26 September 2012 in Artificial Organs
Verified
Journal Article
Closed access
PDF file
YKYasuo Kokubo
Yasuo Kokubo
KUKenzo Uchida
Kenzo Uchida
HOHisashi Oki
Hisashi Oki
KNKohei Negoro
Kohei Negoro
KNKouki Nagamune
Kouki Nagamune
HBHisatoshi Baba
Hisatoshi Baba

6 June 2022 in Immunologic Research
Verified
Journal Article
Closed access
PDF file
NNNoriyuki Numao
Noriyuki Numao
SKShogo Kawaguchi
Shogo Kawaguchi
JDJiangli Ding
Jiangli Ding
TKTakao Karasawa
Takao Karasawa
KSKazuhiko Seya
Kazuhiko Seya
TITadaatsu Imaizumi
Tadaatsu Imaizumi